Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts

Daisuke Hashiguchi, Hidefumi Fukushima, Midori Nakamura, Kazumasa Morikawa, Hisataka Yasuda, Nobuyuki Udagawa, Kenshi Maki, Eijiro Jimi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Mineral trioxide aggregate (MTA) is a therapeutic, endodontic repair material that is reported to exhibit calcified tissue-conductive activity. The aim of this study was to investigate whether MTA may prevent osteoclast differentiation in vitro. MTA solution, but not other commonly used retrofilling materials, such as Dycal, Super-EBA, or intermediate restorative material (IRM) solution, dose-dependently inhibited osteoclastogenesis in cocultures of mouse bone marrow cells (BMCs) with primary osteoblast cells (POBs) induced by 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D 3]. Exogenous CaCl2 medium supplementation did not inhibit osteoclastogenesis in cocultures. Furthermore, MTA solution did not affect receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis, suggesting that POBs are targets of MTA. MTA solution suppressed the 1α,25(OH)2D3-induced reduction of osteoprotegerin (OPG) mRNA and protein production without changing RANKL expression in POBs. Consistent with this result, MTA solution did not inhibit osteoclastogenesis in cocultures of BMCs and POBs from OPG-deficient mice. Therefore, the maintenance of OPG expression in POBs appears to be critical for the inhibitory effect of MTA solution on osteoclast differentiation.

Original languageEnglish
Pages (from-to)358-364
Number of pages7
JournalJournal of Biomedical Materials Research - Part A
Volume96 A
Issue number2
DOIs
Publication statusPublished - Feb 1 2011
Externally publishedYes

Fingerprint

Osteoprotegerin
Osteoblasts
Minerals
Bone
Osteoclasts
mineral trioxide aggregate
Calcitriol
Repair
Ligands
Cells
Tissue
Proteins
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Ceramics and Composites
  • Biomaterials
  • Biomedical Engineering
  • Metals and Alloys

Cite this

Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts. / Hashiguchi, Daisuke; Fukushima, Hidefumi; Nakamura, Midori; Morikawa, Kazumasa; Yasuda, Hisataka; Udagawa, Nobuyuki; Maki, Kenshi; Jimi, Eijiro.

In: Journal of Biomedical Materials Research - Part A, Vol. 96 A, No. 2, 01.02.2011, p. 358-364.

Research output: Contribution to journalArticle

Hashiguchi, Daisuke ; Fukushima, Hidefumi ; Nakamura, Midori ; Morikawa, Kazumasa ; Yasuda, Hisataka ; Udagawa, Nobuyuki ; Maki, Kenshi ; Jimi, Eijiro. / Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts. In: Journal of Biomedical Materials Research - Part A. 2011 ; Vol. 96 A, No. 2. pp. 358-364.
@article{d8b231b8549a4012b7f55b41c74fc48b,
title = "Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts",
abstract = "Mineral trioxide aggregate (MTA) is a therapeutic, endodontic repair material that is reported to exhibit calcified tissue-conductive activity. The aim of this study was to investigate whether MTA may prevent osteoclast differentiation in vitro. MTA solution, but not other commonly used retrofilling materials, such as Dycal, Super-EBA, or intermediate restorative material (IRM) solution, dose-dependently inhibited osteoclastogenesis in cocultures of mouse bone marrow cells (BMCs) with primary osteoblast cells (POBs) induced by 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D 3]. Exogenous CaCl2 medium supplementation did not inhibit osteoclastogenesis in cocultures. Furthermore, MTA solution did not affect receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis, suggesting that POBs are targets of MTA. MTA solution suppressed the 1α,25(OH)2D3-induced reduction of osteoprotegerin (OPG) mRNA and protein production without changing RANKL expression in POBs. Consistent with this result, MTA solution did not inhibit osteoclastogenesis in cocultures of BMCs and POBs from OPG-deficient mice. Therefore, the maintenance of OPG expression in POBs appears to be critical for the inhibitory effect of MTA solution on osteoclast differentiation.",
author = "Daisuke Hashiguchi and Hidefumi Fukushima and Midori Nakamura and Kazumasa Morikawa and Hisataka Yasuda and Nobuyuki Udagawa and Kenshi Maki and Eijiro Jimi",
year = "2011",
month = "2",
day = "1",
doi = "10.1002/jbm.a.32990",
language = "English",
volume = "96 A",
pages = "358--364",
journal = "Journal of Biomedical Materials Research - Part A",
issn = "1549-3296",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts

AU - Hashiguchi, Daisuke

AU - Fukushima, Hidefumi

AU - Nakamura, Midori

AU - Morikawa, Kazumasa

AU - Yasuda, Hisataka

AU - Udagawa, Nobuyuki

AU - Maki, Kenshi

AU - Jimi, Eijiro

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Mineral trioxide aggregate (MTA) is a therapeutic, endodontic repair material that is reported to exhibit calcified tissue-conductive activity. The aim of this study was to investigate whether MTA may prevent osteoclast differentiation in vitro. MTA solution, but not other commonly used retrofilling materials, such as Dycal, Super-EBA, or intermediate restorative material (IRM) solution, dose-dependently inhibited osteoclastogenesis in cocultures of mouse bone marrow cells (BMCs) with primary osteoblast cells (POBs) induced by 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D 3]. Exogenous CaCl2 medium supplementation did not inhibit osteoclastogenesis in cocultures. Furthermore, MTA solution did not affect receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis, suggesting that POBs are targets of MTA. MTA solution suppressed the 1α,25(OH)2D3-induced reduction of osteoprotegerin (OPG) mRNA and protein production without changing RANKL expression in POBs. Consistent with this result, MTA solution did not inhibit osteoclastogenesis in cocultures of BMCs and POBs from OPG-deficient mice. Therefore, the maintenance of OPG expression in POBs appears to be critical for the inhibitory effect of MTA solution on osteoclast differentiation.

AB - Mineral trioxide aggregate (MTA) is a therapeutic, endodontic repair material that is reported to exhibit calcified tissue-conductive activity. The aim of this study was to investigate whether MTA may prevent osteoclast differentiation in vitro. MTA solution, but not other commonly used retrofilling materials, such as Dycal, Super-EBA, or intermediate restorative material (IRM) solution, dose-dependently inhibited osteoclastogenesis in cocultures of mouse bone marrow cells (BMCs) with primary osteoblast cells (POBs) induced by 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D 3]. Exogenous CaCl2 medium supplementation did not inhibit osteoclastogenesis in cocultures. Furthermore, MTA solution did not affect receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis, suggesting that POBs are targets of MTA. MTA solution suppressed the 1α,25(OH)2D3-induced reduction of osteoprotegerin (OPG) mRNA and protein production without changing RANKL expression in POBs. Consistent with this result, MTA solution did not inhibit osteoclastogenesis in cocultures of BMCs and POBs from OPG-deficient mice. Therefore, the maintenance of OPG expression in POBs appears to be critical for the inhibitory effect of MTA solution on osteoclast differentiation.

UR - http://www.scopus.com/inward/record.url?scp=78650441822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650441822&partnerID=8YFLogxK

U2 - 10.1002/jbm.a.32990

DO - 10.1002/jbm.a.32990

M3 - Article

C2 - 21171155

AN - SCOPUS:78650441822

VL - 96 A

SP - 358

EP - 364

JO - Journal of Biomedical Materials Research - Part A

JF - Journal of Biomedical Materials Research - Part A

SN - 1549-3296

IS - 2

ER -